Researchers are exploring the use of base edited "universal" donor CAR T-cell strategies to treat certain types of blood cancer, including acute myeloid leukemia and T-cell acute lymphoblastic leukemia. These strategies involve engineering immune cells to evade the immune system and target cancer cells, with some studies showing promise in inducing remission in patients with relapsed or refractory disease. The approach is part of a broader effort to develop and expand the applications of CAR T-cell therapy for various diseases.